

TABLE OF CONTENTS

Book 6

Preface	i
Editorial Board	ii
Book 6 Panel	iii
Continuing Education and Program Evaluation Instructions	viii
Roles of ACCP and BPS	xi

Infectious Diseases I

ZOONOSES

Learning Objectives	1
Introduction	1
Viral Zoonoses	2
Mosquito-borne Viral Zoonoses	2
St. Louis Encephalitis	2
Background	2
Epidemiology and Microbiology	3
Clinical Manifestations/Laboratory Findings	4
Laboratory Diagnostic Methods	6
Treatment	6
Dengue	6
Background	6
Epidemiology and Microbiology	6
Clinical Manifestations/Laboratory Findings	8
Laboratory Diagnostic Methods	8
Treatment	8
Tick-borne Viral Zoonoses	9
Colorado Tick Fever	9
Background	9
Epidemiology and Microbiology	9
Clinical Manifestations/Laboratory Findings	9
Laboratory Diagnostic Methods	9

Treatment	9
Animal-borne Viral Zoonoses	9
Hantavirus	9
Background	9
Epidemiology and Microbiology	10
Clinical Manifestations/Laboratory Findings	10
Hemorrhagic Fever and Renal Syndrome	11
Hantavirus Pulmonary Syndrome	11
Laboratory Diagnostic Methods	11
Treatment	12
Rabies	12
Background	12
Epidemiology and Microbiology	12
Clinical Manifestations/Laboratory Findings	13
Laboratory Diagnostic Methods	14
Treatment	14
Postexposure Rabies Treatment	14
Preexposure Rabies Prevention	15
Brain Tissue Vaccines	15
Other Therapies	15
Bacterial Zoonoses	15
Tick-borne Bacterial Zoonoses	16
Ehrlichiosis	16
Background	16
Epidemiology and Microbiology	16
Human Monocytic Ehrlichiosis	16
Human Granulocytic Ehrlichiosis	16
Human Granulocytic Ehrlichiosis Caused by <i>Ehrlichia ewingii</i>	16
Clinical Manifestations/Laboratory Findings	16
Laboratory Diagnostic Methods	17
Treatment	17
Rocky Mountain Spotted Fever	18
Background	18
Epidemiology and Microbiology	18
Clinical Manifestations/Laboratory Findings	18
Laboratory Diagnostic Methods	19
Treatment	19
Tularemia	19

Background	19
Epidemiology and Microbiology	19
Clinical Manifestations/Laboratory Findings	20
Laboratory Diagnostic Methods	21
Treatment	21
Spirochetal Zoonoses	21
Tick-borne Spirochetal Zoonoses	21
Lyme Disease	21
Background	21
Epidemiology and Microbiology	21
Clinical Manifestations/Laboratory Findings	22
Laboratory Diagnostic Methods	22
Treatment	23
Tick-borne Relapsing Fever	23
Background	23
Epidemiology and Microbiology	23
Clinical Manifestations/Laboratory Findings	23
Laboratory Diagnostic Methods	23
Treatment	25
Animal-borne Spirochetal Zoonoses	25
Leptospirosis	25
Background	25
Epidemiology and Microbiology	25
Clinical Manifestations/Laboratory Findings	25
Laboratory Diagnostic Methods	26
Treatment	26
Cat-scratch Disease	27
Background	27
Epidemiology and Microbiology	27
Clinical Manifestations/Laboratory Findings	27
Laboratory Diagnostic Methods	27
Treatment	27
Brucellosis	28
Background	28
Epidemiology and Microbiology	28
Clinical Manifestations/Laboratory Findings	28
Laboratory Diagnostic Methods	29
Treatment	29
Q-fever	29
Background	29
Epidemiology and Microbiology	29
Clinical Manifestations/Laboratory Findings	30
Laboratory Diagnostic Methods	30
Treatment	31
Parasitic Zoonoses	31
Tick-borne Protozoal Zoonosis	31
Babesiosis	31
Background	31
Epidemiology and Microbiology	31
Clinical Manifestations/Laboratory Findings	32
Laboratory Diagnostic Methods	32
Treatment	32
Animal-borne Protozoal Zoonosis	33
Cryptosporidiosis	33
Background	33
Epidemiology and Microbiology	33

Clinical Manifestations/Laboratory Findings	34
Laboratory Diagnostic Methods	34
Treatment	34
Conclusion	35
Annotated Bibliography	35
Self-Assessment Questions	37
EMERGING VIRAL INFECTIONS	
Learning Objectives	43
Introduction	43
Overview of Emerging Viral Infections	44
Historical Perspective of Emerging Infections	44
General Factors Influencing Emerging Pathogens	44
Factors Influencing Emergence and Reemergence	44
Ecological Changes	44
Human Demographics and Behavior	44
International Travel and Commerce	44
Technology and Industry	45
Microbial Adaptation and Change	45
Breakdown in Public Health Infrastructure	45
Pathogen-specific Factors Influencing Emergence	45
Preparedness for Emerging Infections	46
Public Health Infrastructure	46
Surveillance	46
Research	46
Prevention and Control	47
Microbial Transmission Routes	47
Transmission of Respiratory Pathogens	47
Influenza	47
Virology and Epidemiology	47
Virology	47
Influenza's Historical Cycle	48
Clinical Characteristics	48
Disease	48
Diagnosis	48
Complications	49
Infection Control Precautions	49
Influenza Transmission	49
Protective Measures	50
Vaccination	51
Effectiveness	51
Safety	52
Recommendations and Clinical Application	52
Pharmacotherapy	54
Treatment	54
Chemoprophylaxis	55
Future Directions of Influenza Pharmacotherapy	55
Influenza Pandemics and Preparedness	56
Severe Acute Respiratory Syndrome	57
History	58
Clinical Characteristics	58
Cause and Transmission	58
Disease	59
Case Detection, Diagnosis, and Reporting	59
Infection Control	60

Pharmacotherapy	.60
Future Possibilities	.60
West Nile Virus	.61
Virology, Ecology, and Transmission	.61
History and Epidemiology	.62
Surveillance	.62
Clinical Characteristics	.62
Disease	.62
Diagnosis and Reporting	.63
Pharmacotherapy	.63
Prevention	.64
Mosquito Population Reduction	.64
Personal Protective Measures	.64
Future Possibilities	.65
Potential Emerging Viral Infections	.65
Rift Valley Fever	.65
Dengue Hemorrhagic Fever	.65
Implications for the United States	.65
Conclusion	.65
Annotated Bibliography	.66
Self-Assessment Questions	.67

FOODBORNE ILLNESSES

Learning Objectives	.71
Introduction	.71
Incidence	.71
Surveillance	.72
Bacterial Illnesses	.73
Epidemiology	.73
<i>Staphylococcus aureus</i>	.73
<i>Bacillus cereus</i>	.73
<i>Clostridium</i> Species	.75
<i>Campylobacter jejuni</i>	.75
<i>Listeria monocytogenes</i>	.75
<i>Salmonella</i> Species	.75
<i>Shigella</i> Species	.75
<i>Escherichia coli</i>	.76
<i>Vibrio</i> Species	.76
<i>Yersinia enterocolitica</i>	.77
Laboratory Diagnosis	.77
Treatment	.77
Rehydration Therapy	.77
Antidiarrheal Therapy	.78
Antimicrobial 01 Antitoxin Therapy	.79
Prevention	.79
Viral Diseases	.81
Epidemiology	.81
Norwalk-like Viruses	.81
Hepatitis A	.81
Diagnosis	.81
Treatment	.82
Parasitic Diseases	.82
Epidemiology	.82
Diagnosis	.83
Treatment	.83
Traveler's Diarrhea	.83

Epidemiology	.83
Treatment	.84
Prevention	.84
Chemicals and Other Miscellaneous Agents	.85
Heavy Metal Poisonings	.85
Mushroom Poisonings	.85
Chinese Restaurant Syndrome	.85
Fish Poisonings	.85
Prion Diseases	.86
Pathophysiology	.86
Epidemiology	.87
Diagnosing BSE and vCJD	.88
Potential Therapeutic Options	.89
Infection Control	.89
Future Implications	.90
Pharmacist's Role in Managing Foodborne Illnesses	.91
Annotated Bibliography	.91
Self-Assessment Questions	.93

Infectious Diseases II

ATYPICAL MYCOBACTERIA

Learning Objectives	.99
Introduction	.99
Pathophysiology	.100
Bacteriology	.100
Pathogenesis and Epidemiology	.101
Diagnosis	.104
General Principles	.104
Pulmonary Infection	.105
Skin and Skin Structure Infection	.106
Lymphadenitis	.107
Disseminated Infection	.107
Quality Patient Care	.107
General Principles	.107
Pharmacotherapy—Drug Class Overviews	.108
Traditional Antimycobacterial Drugs	.108
Isoniazid	.108
Rifampin and Rifabutin	.108
Ethambutol	.109
New Macrolides	.109
Fluoroquinolones	.110
Aminoglycosides	.112
β -Lactams and Carbapenems	.112
Miscellaneous Drugs	.112
Treatment	.113
Pulmonary Infection	.113
<i>Mycobacterium avium</i> Complex	.113
<i>Mycobacterium kansasii</i>	.113
<i>Mycobacterium xenopi</i>	.113
<i>Mycobacterium malmoense</i>	.115
Rapid-growing Atypical Mycobacteria	.115
Extrapulmonary Infection Sites	.116
Cutaneous Infection	.116
<i>Mycobacterium marinum</i>	.116
<i>Mycobacterium ulcerans</i>	.116

<i>Mycobacterium haemophilum</i>	116
<i>Mycobacterium leprae</i>	116
Rapid-growing Mycobacteria	116
Lymphadenitis	117
Bone and Joint Infection	117
Catheter-related Infections	117
Disseminated Infection	117
<i>Mycobacterium avium</i> Complex	118
<i>Mycobacterium kansasii</i>	118
<i>Mycobacterium haemophilum</i>	119
<i>Mycobacterium genavense</i>	119
<i>Mycobacterium chelonae</i>	119
Prevention of Disease	119
Conclusions	119
Annotated Bibliography	120
Self-Assessment Questions	121

**HUMAN IMMUNODEFICIENCY VIRUS/
ACQUIRED IMMUNE DEFICIENCY SYNDROME**

Learning Objectives	127
Introduction	127
Diagnosis	128
Epidemiology	128
Viral Transmission	128
Pathophysiology	129
Etiology	129
Clinical Course	129
Quality Pharmaceutical Care	130
Antiretroviral Drug Therapy	130
Occupational and Nonoccupational Postexposure Prophylaxis	133
Resistance Testing	136
Monitoring	136
Opportunistic Infections	138
Non-pharmacological Considerations	138
Pharmacists' Role in the Care of People with HIV	140
Conclusion	140
Annotated Bibliography	140
Self-Assessment Questions	143

Infectious Diseases III

GRAM-POSITIVE INFECTIONS

Learning Objectives	149
Introduction	149
Background	149
History of Resistance	150
Microbiology	150
Resistance Mechanisms	150
Mechanisms of β -Lactam Resistance	150
β -Lactam Resistance in <i>Streptococcus</i> <i>pneumoniae</i>	150
β -Lactam Resistance in <i>Staphylococcus</i> Species	151
β -Lactam Resistance in <i>Enterococcus</i> Species	151
Mechanisms of Glycopeptide Resistance	151

Glycopeptide Resistance in <i>S. pneumoniae</i>	151
Glycopeptide Resistance in <i>Staphylococcus</i> Species	154
Glycopeptide Resistance in <i>Enterococcus</i> Species	155
Mechanisms of Macrolide Resistance	155
Mechanisms of Fluoroquinolone Resistance	155
Mechanism of Rifampin Resistance	156
Mechanisms of Aminoglycoside Resistance	156
Mechanism of Mupirocin Resistance in <i>Staphylococcus</i> Species	156
Mechanism of Linezolid Resistance	156
Mechanism of Lincosamide Resistance	157
Mechanism of Streptogramin Resistance	157
Multiple Antibiotic Drug Resistance	157
<i>Streptococcus pneumoniae</i> Infections	157
Epidemiology	157
Risk Factors for Resistant Pneumococcal Infections	157
Pathophysiology	158
Pharmacodynamic Considerations	158
β -Lactams	159
Macrolides and Ketolides	159
Fluoroquinolones	159
Therapy Choices for <i>Streptococcus pneumoniae</i>	159
Otitis Media	160
Sinusitis	160
Community-acquired Pneumonia	161
Meningitis	163
Antibiotic Drugs to Treat Vancomycin-tolerant <i>Streptococcus pneumoniae</i> Infections	164
Preventing the Emergence of Antibiotic-resistant Pneumococci	164
Staphylococcal Infections	164
Epidemiology	165
Risk Factors for Resistant Staphylococcal Infections	165
Pathophysiology	165
Considerations in Treatment and Treatment Options	165
β -Lactam-resistant Staphylococcal Species	165
Methicillin-resistant <i>Staphylococcus aureus</i>	166
Vancomycin-intermediate <i>S. aureus</i> and Vancomycin-resistant <i>S. aureus</i>	166
Prevention of Repeat MRSA Infections in Colonized Patients	167
Enterococcal Infections	167
Epidemiology	168
Risk Factors for VRE	168
Pathophysiology	168
Therapy Choices for Clinical Infections	168
Combination Therapy	169
Prevention of Emergence and Spread of VRE	169
Goals of Therapy for Gram-positive Infections	169
Clinical Overview of Drugs for Gram-positive Infections	170

β-Lactams	170	Intravascular Access Device Dressing Regimens ..	189
Glycopeptides	170	Scheduled Replacements of IVADs	189
Macrolides and Ketolides	170	Topical Antimicrobial/Antiseptic Drugs	189
Fluoroquinolones	171	Interventions Related to the Type of IVAD	190
Tetracyclines	171	Intravascular Access Device Materials and In-Line	
Sulfa Drugs	171	Filters	190
Clindamycin	171	Antimicrobial- or Antiseptic-impregnated	
Linezolid	171	or -coated IVADs	190
Streptogramins	172	Introduction	190
Daptomycin	172	Benzalkonium-treated IVADs	190
Infection Control	172	Silver-impregnated Catheter Hubs	190
Pharmacist's Role in Managing Gram-positive		Platinum-, Silver-, and Carbon-impregnated	
Infections	173	IVADs	190
Conclusion	174	Chlorhexidine-Silver Sulfadiazine- and	
Annotated Bibliography	174	Minocycline-Rifampin-impregnated IVADs ..	190
Self-Assessment Questions	177	Critical Analysis of the Value and	
		Cost-Effectiveness of	
		Antimicrobial-impregnated IVADs	191
		Antibiotic Lock Prophylaxis	191
INTRAVASCULAR ACCESS DEVICE-RELATED		Treatment of CRBSIs	192
INFECTIONS		General Considerations	192
Learning Objectives	183	Efficacy of Treatment Regimens for CRBSIs	192
Introduction	183	Therapy Duration	193
Description of Various Commonly Used IVADs ..	183	Salvage of the IVAD During Therapy of CRBSIs ..	193
Description of Various Important Terminologies		Systemic Antimicrobial Drug Therapy	193
associated with CRBSIs	184	Description of Antibiotic Lock Therapy	
Epidemiology of CRBSIs	185	and Pharmacological Considerations	193
Quantification of Rates of CRBSIs	185	Effectiveness of Antibiotic Lock Therapy	193
Specific Factors Influencing Rates of CRBSIs ..	185	Treatment Considerations Based on the Type	
Microbiology of CRBSIs	185	of IVAD	195
Morbidity, Mortality, and Economic Implications		Short-term, Nontunneled CVCs	195
of CRBSIs	186	Low-risk CRBSIs	195
Pathogenesis of CRBSIs	186	Moderate- and High-risk CRBSIs	195
Routes of Infection Development	186	Tunneled CVCs or Other Surgically	
The Importance of Biofilms in the Pathogenesis		Implanted IVADs	195
and Management of CRBSIs	186	Hemodialysis Catheters	196
Definition of Biofilms/General Characteristics ..	186	Intravascular Access Device Colonization without	
Factors Related to IVADs that Influence Biofilm		CRBSI	197
Development	187	Important Considerations for CRBSIs Caused	
Antimicrobial Resistance of Biofilms	187	by Specific Pathogens	197
Diagnosis of CRBSIs	187	<i>Staphylococcus aureus</i>	197
General Clinical Findings	187	Enterococci	198
Quantitative and Semiquantitative Culture Methods		Gram-negative Bacilli	198
for Removed IVADs	187	<i>Candida</i> and Other Fungal Pathogens	198
Culture of Blood Samples	188	Conclusions	198
Comparative Quantitative Blood Cultures	188	Annotated Bibliography	198
Differential Time to Positivity of Percutaneous		Self-Assessment Questions	201
and IVAD-derived Blood Samples	188		
Rapid Diagnostic Tests for Diagnosing CRBSIs ..	188	SUPERFICIAL SKIN INFECTIONS	
Preventing CRBSIs	188	Learning Objectives	207
Interventions Related to the Insertion of the IVAD ..	188	Superficial Skin Infections	207
Site of IVAD Insertion	188	Introduction	207
Aseptic Technique and Hand Hygiene	189	Tinea	207
Skin Antisepsis Products	189	Introduction	207
Systemic Antibiotic Prophylaxis	189	Pathophysiology	207
Interventions Related to the Care and Use		Etiology	207
of the IVAD	189		
Aseptic Technique and Hand Hygiene	189		

Clinical Presentation	208
Diagnosis	208
Quality Pharmaceutical Care	208
Pharmacotherapy—Topical Antifungal drugs	208
Tolnaftate	208
Haloprogin	208
Ciclopirox	208
Imidazoles	208
Allylamines	209
Benzylamines	209
Antifungal Drug and Steroid Combinations	209
Pharmacotherapy—Oral Antifungal Drugs	209
Griseofulvin	209
Azole Antifungal Drugs	210
Terbinafine	210
Treatment Plan	211
Tinea capitis	211
Tinea barbae	211
Tinea corporis	211
Tinea cruris	211
Tinea pedis	211
Tinea manuum	212
Tinea unguium	213
Tinea versicolor	214
Candidiasis	214
Treatment Failures and Resistance	214
Special Populations	214
Role of the Clinical Pharmacist	215
Patient Education	215
Pediculosis	216
Introduction	216
Etiology	216
Transmission	216
Epidemiology	216
Clinical Presentation	216
Diagnosis	216
Quality Pharmaceutical Care	216
Pharmacotherapy	218
Pyrethrins 0.33% plus Piperonyl Butoxide 4%	218
Permethrin 1%	218
Malathion 0.5%	218
Lindane 1%	218
Trimethoprim-sulfamethoxazole	218
Ivermectin	218
Natural and Occlusive Products	219
Manual Removal	219
Treatment Plan	219
Pediculicide Treatment Failures and Resistance	219
Treatment of Special Patient Populations	220
Environmental Interventions	220
Role of the Clinical Pharmacist	220
Scabies	220
Introduction	220
Etiology	220
Transmission	220
Epidemiology	221

Clinical Presentation	221
Diagnosis	221
Quality Pharmaceutical Care	221
Pharmacotherapy	221
Permethrin 5% Cream	221
Lindane 1% Lotion	221
Crotamiton 10% Cream	221
Ivermectin	221
Treatment Plan	221
Environmental Interventions	222
Treatment of Special Populations	222
Role of the Clinical Pharmacist	222
Cellulitis	222
Introduction	222
Pathophysiology	222
Etiology	222
Clinical Presentation	222
Diagnosis	223
Prognosis	223
Quality Pharmaceutical Care	223
Pharmacotherapy	223
β -Lactams	223
Fluoroquinolones	225
Macrolides and Azalides	225
Lincosamide	225
Oxazolidinone	226
Therapeutic Goals and Outcomes	226
Time to Initial Response and Therapy	226
Duration	226
Drug Selection	226
Efficacy	226
Effectiveness	226
Non-pharmacological Therapy	226
Considerations in Patients who Experience	226
Treatment Failures	226
Role of the Clinical Pharmacist	227
Patient Education	227
Preventing Cellulitis in High-risk Patients	227
Summary	227
Annotated Bibliography	227
Self-Assessment Questions	229

Infectious Diseases IV

NOSOCOMIAL GRAM-NEGATIVE INFECTIONS

Learning Objectives	235
Introduction	235
Changing Epidemiology of Gram-negative	235
Infection	235
Epidemiology	235
Mortality	236
Risk Factors	236
Appropriate Versus Inappropriate Therapy	236
Resistance Issues	237
Rates	237
Factors That Promote Antimicrobial Resistance	237

Health Care Setting Factors	237
Patient-specific Factors	238
Specific Resistance Mechanisms	238
AmpC-type β -Lactamase	238
Extended-spectrum β -Lactamase	239
Efflux Systems	240
Porin Channel Modification	241
Specific Organisms	241
<i>Pseudomonas aeruginosa</i>	241
<i>Acinetobacter</i> Species	243
<i>Stenotrophomonas maltophilia</i>	243
<i>Escherichia coli</i>	244
Pharmacotherapy	244
Pharmaceutical Care: Optimizing Outcome	244
Factors Guiding Antimicrobial Therapy	244
Strategies for Appropriate use	244
Dosing	244
Guidelines	245
Therapy	246
Bloodstream Infections	246
Pneumonia	247
Ventilator-associated Pneumonia	247
Systems Management	249
Selective Decontamination of the Digestive Tract	249
Antibiotic Restriction and Rotation Programs	249
Conclusion	251
Annotated Bibliography	251
Self-Assessment Questions	253

TREATMENT OF PRIMARY AND OPPORTUNISTIC INVASIVE MYCOSES

Learning Objectives	257
Introduction	257
Microbiology of Fungi	258
Fungal Cell Biology	258
Laboratory Diagnosis of Fungal Infections	259
Antifungal Drug Susceptibility Testing	260
Systemic Antifungal Therapy	261
Amphotericin B	261
Infusion-related Reactions	261
Nephrotoxicity	265
Fluoropyrimidines	265
Flucytosine	265
Azole Antifungal Drugs	266
Itraconazole	266
Fluconazole	266
Voriconazole	266
Posaconazole	267
Azole Drug Interactions	267
Echinocandins	267
Combination Antifungal Therapy	268
Primary Systemic Mycoses	269
Histoplasmosis	269
Pathogenesis and Clinical Presentation	270
Laboratory Diagnosis	270
Treatment	270

Blastomycosis	271
Pathogenesis and Clinical Presentation	273
Laboratory Diagnosis	274
Treatment	274
Coccidioidomycosis	275
Pathogenesis and Clinical Presentation	275
Laboratory Diagnosis	275
Treatment	276
Opportunistic Systemic Mycoses	276
Invasive Candidiasis	277
Pathogenesis and Clinical Presentation	277
Laboratory Diagnosis	277
Treatment	278
Cryptococcosis	279
Pathogenesis and Clinical Presentation	279
Laboratory Diagnosis	280
Treatment	280
Invasive Aspergillosis	281
Pathogenesis and Clinical Presentation	281
Laboratory Diagnosis	282
Treatment	282
Less Common Opportunistic Moulds	283
Fusariosis	283
Zygomycosis	283
Antifungal Prophylaxis	284
Prophylaxis in Neutropenic Patients	284
Prophylaxis in Non-neutropenic Patients	284
Conclusion	285
Annotated Bibliography	285
Self-Assessment Questions	287